COL4A3 and Alport syndrome: Based on the protective effect against renal fibrosis and inflammation of anti-miR-21 oligonucleotides in Col4α3−/− mouse model, a Phase 2, randomized, double-blind, placebo-controlled clinical trial (ClinicalTrials.gov identifier NCT02855268) to assess the safety, efficacy, pharmacodynamics, and pharmacokinetics of an anti-miR-21 agent RG-012 in patients with Alport syndrome is in progress [98].